Healthcare Policy

House Republicans Intensify Scrutiny of Medicare Advantage with Sweeping Subpoenas to Major Insurers

In a significant escalation of congressional oversight, the Republican-led U.S. House Energy and Commerce Committee recently issued subpoenas to eight major health insurance companies, demanding extensive documentation related to their Medicare Advantage operations. This aggressive move, reported by Axios, targets alleged overpayments, aggressive marketing tactics, and restrictive prior authorization practices within the rapidly expanding private […]

House Republicans Intensify Scrutiny of Medicare Advantage with Sweeping Subpoenas to Major Insurers Read More »

Lupin’s $90 Million Astellas Settlement: Navigating the Complexities of Pharmaceutical Patent Litigation

India’s Lupin Limited recently settled a protracted patent infringement dispute with Japan’s Astellas Pharma in the United States, agreeing to pay $90 million to resolve claims related to Astellas’s blockbuster prostate cancer drug, Xtandi (enzalutamide). This significant financial resolution, announced to the market, aims to conclude the legal battle over Lupin’s proposed generic version of

Lupin’s $90 Million Astellas Settlement: Navigating the Complexities of Pharmaceutical Patent Litigation Read More »